The estimate should start with retinal imaging and a treatment plan
UKE lists OCT, retinal examination and fluorescein angiography in the assessment of diabetic retinal disease, while Cologne documents OCT and angiographic imaging in its retina services. The hospital therefore needs enough information to define whether the eye has center-involving edema, ischemia, traction or another complication before pricing the treatment episode.
- Retina-specialist consultation
- Visual-acuity assessment
- Macular OCT in both eyes
- Fundus imaging when required
- Fluorescein, ICG or OCT angiography when clinically indicated
- Review of previous injection and laser response
Repeated injections can dominate the longitudinal cost
UKE describes intravitreal therapy as the primary modern treatment pathway for diabetic macular edema, and University Hospital Cologne documents both VEGF inhibitors and corticosteroid injections for DME. The total financial burden depends on the series of treatment and monitoring visits, not only the procedure fee for one injection.
- Planned intravitreal medicine
- Number of visits assumed in the initial estimate
- OCT and specialist review around treatment visits
- Criteria for repeating, extending or switching treatment
- What happens financially if more treatment is required than initially estimated
Steroid treatment changes both monitoring and cost
Selected eyes may be considered for intravitreal corticosteroid treatment. Lens status, cataract risk, intraocular pressure and glaucoma history can affect whether this pathway is appropriate and what additional monitoring is required. A quotation should identify the planned medicine and the pressure-monitoring pathway rather than grouping all DME injections under one price.
Laser or surgery should be quoted only when clinically relevant
UKE and Cologne document retinal laser in diabetic retinal care, while vitrectomy is reserved for selected complications such as vitreous hemorrhage or tractional membranes. These are different treatment episodes with different resource use. They should not be silently bundled into a generic 'DME package'.
Long-term follow-up may be better transferred closer to home
DME can require months or longer of monitoring and repeated treatment. International patients should ask whether the German visit is intended as a second opinion, an initial treatment phase or a long-term injection program. A safe handover to a retina specialist near home may reduce travel burden without interrupting medically necessary follow-up.
- Expected number of visits in Germany
- When follow-up can transfer to the home ophthalmologist
- Which OCT images and treatment notes should travel with the patient
- What symptoms require urgent local review
- Whether the fellow eye needs its own monitoring plan
Why we do not publish a made-up fixed price
German university hospitals prepare international-patient estimates after medical review and a defined treatment plan. LMU states that it does not publish a general treatment price list and that final costs depend on care actually delivered; UKE describes an individualized cost estimate after the responsible department defines the treatment plan. A hospital-specific written quotation is therefore more useful than an unsourced headline price.
Official sources
- Cost Plan — LMU Klinikum International Patient Office ↗
- International patient process and cost estimate — University Medical Center Hamburg-Eppendorf (UKE) ↗
- Diabetic retinal disease – diagnosis and treatment — University Medical Center Hamburg-Eppendorf (UKE) ↗
- Ophthalmology MVZ – DME, IVOM and retinal diagnostics — University Hospital Cologne ↗
- Retinal surgery, laser treatment and intravitreal injections — University Hospital Cologne ↗